Last reviewed · How we verify
Omalizimab
At a glance
| Generic name | Omalizimab |
|---|---|
| Also known as | Xolair |
| Sponsor | Rabin Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression (PHASE4)
- Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omalizimab CI brief — competitive landscape report
- Omalizimab updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI